Advertisement

Topics

Latest "Biosciences" News Stories

07:54 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "Biosciences" found in our extensive news archives from over 250 global news sources.

More Information about Biosciences on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biosciences for you to read. Along with our medical data and news we also list Biosciences Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biosciences Companies for you to search.

Showing "Biosciences" News Articles 1–25 of 1,300+

Relevant

Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion

Illumina, Inc. and Pacific Biosciences announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted avera...


Strategic partnership forms between Taconic Biosciences and Cyagen Biosciences

A strategic partnership has been formed between Taconic Biosciences and Cyagen Biosciences — both global companies that generate custom genetically engineered rodent models and associated services.

Illumina To Acquire Pacific Biosciences At $8.00/shr

SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN) and Pacific Biosciences (PACB) announced an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in a...


Kuros Biosciences Ltd.: Kuros Biosciences appoints Strategic Advisory Board

Kuros Biosciences appoints Strategic Advisory Board Schlieren (Zurich), Switzerland, September 25, 2018 - Kuros Biosciences (SIX: KURN) today announced the formation of its Strategic Advisory Boar...

Kuros Biosciences Ltd.: Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer

Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer Schlieren (Zurich), Switzerland, August 23, 2018 Kuros Biosciences AG (SIX: KURN) announced today the appointment of Pascal Long...

FSD Pharma to acquire Therapix Biosciences

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Biosciences shareholders will receive The post FSD Pharma to acquire Therapix Biosciences appeared first on Pharma Business review.

Illumina to acquire Pacific Biosciences for $1.2bn

California-based Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems The company’s technology is claimed to offer high accuracy, ultra-long reads, uniform coverage, and the The post Illumina to acquire Pacific Biosciences for $1.2bn appeared first on Compelo Medical Devices.

FSD Pharma signs binding LOI to buy Therapix Biosciences

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Biosciences shareholders will receive The post FSD Pharma signs binding LOI to buy Therapix Biosciences appeared first on Pharma Business review.

#Cannabisstocks: Sproutly (CSE:SPR) Closes Acquisition of Infusion Biosciences Canada and SSM

VANCOUVER, British Columbia - August 1, 2018 (Investorideas.com Newswire) Sproutly Canada, Inc. (CSE:SPR) (FRA:38G) ("Sproutly" or the "Company") is pleased to announce that it has completed the acquisition of all of the issued and outstanding shares of Infusion Biosciences Canada Inc. ("Infusion Biosciences Canada") and SSM Partners Inc. ("SSM")

Eli Lilly closes $1.6bn ARMO BioSciences acquisition

Eli Lilly has completed the acquisition of immuno-oncology company ARMO BioSciences in an all-cash deal valued at nearly $1.6bn. Lilly...Read More... The post Eli Lilly closes $1.6bn ARMO BioSciences acquisition appeared first on Pharmaceutical Technology.

Vortex Biosciences announces management changes

Bob Englert has been promoted from chief technology officer to CEO at Vortex Biosciences, replacing Gene Walther who has resi -More- 

Reveal Biosciences, Science Exchange partner to apply AI to pathology

Reveal Biosciences is a San Diego-based company that’s leading the next generation of quantitative histopathology, combining the latest artificial intelligence (AI) techniques with high-quality histology, immunohistochemistry (IHC) and The post Reveal Biosciences, Science Exchange partner to apply AI to pathology appeared first on Compelo Medical Devices.

BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, The post BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers appeared first on Pharmaceutical Business review.

Kuros Biosciences Ltd.: Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference

Schlieren (Zurich), Switzerland, June 19, 2018 Kuros Biosciences to present promising clinical case studies with MagnetOs at leading spine surgery conference Kuros Biosciences will this week prese...

Xenetic Biosciences Aktie: Was ist hier los?

Xenetic Biosciences arbeitet an innovativen neuen Medikamenten und Behandlungsmethoden, welche unter anderem im Kampf gegen Krebs helfen sollen. An der Börse wird das Unternehmen als Geheimtipp geh...

Roche licenses IPF candidate to Ark Biosciences

Roche’s Genentech Inc. licensed Ark Biosciences Inc. exclusive worldwide development and commercialization rights to its Ph...

Hunt Biosciences, Scott Woodward: The HUNT Study: One of the best kept secrets in the industy.

Filmed at BioEurope 2013, Paul Larsmon talks to Scott Woodward, Business Development Head of HUNT Biosciences about the HUNT Study. A thirty year long study on over 130,000 patients in the Nord-Trøndelag county in Norway. A rich resource for the Pharma industry. HUNT Biosciences is the entry point to a unique set of biological samples and extensive clinical and longitudinal data based on the No...

Akers Biosciences starts strategic review process

Akers Biosciences has begun evaluating "strategic alternatives to maximize shareholder value," its board of directors said.  -More- 

Illumina Acquires Pacific Biosciences for $1.2 Billion

The deal to acquire its rival, Pacific Biosciences, will provide Illumina with a more comprehensive sequencing test at a lower cost.

Vedanta Biosciences initiates Phase I study of VE202 to treat IBD

Vedanta Biosciences has initiated a Phase I clinical study of its live biotherapeutic product (LBP) candidate VE202 for the treatment...Read More... The post Vedanta Biosciences initiates Phase I study of VE202 to treat IBD appeared first on Drug Development Technology.

Kaleido Biosciences raises $101m to advance pipeline

Clinical-stage healthcare company firm Kaleido Biosciences has raised $101m in an oversubscribed series C financing.

Vedanta Biosciences starts phase 1 study of VE202 to treat IBD

Janssen Research & Development is undertaking the study. Vedanta Biosciences had granted the licensing rights of VE202 in 2015 to Janssen Biotech. The microbiome-derived product candidate is being The post Vedanta Biosciences starts phase 1 study of VE202 to treat IBD appeared first on Pharmaceutical Business review.

Pulse Biosciences starts NPS cutaneous wart feasibility study

Pulse Biosciences said the feasibility study will include up to 20 subjects at the Scripps Clinic in San Diego, California, US. Eligible subjects receive NPS treatment(s) followed by The post Pulse Biosciences starts NPS cutaneous wart feasibility study appeared first on Compelo Medical Devices.

Precision BioSciences and Gilead partner in hep B drug development deal

Gilead Sciences Inc. and Precision BioSciences Inc. penned an agreement to discover and develop new treatments for hepatitis ...

Imago BioSciences completes enrolment in Phase l/lla trial of IMG-7289

Imago BioSciences has completed patient enrolment in a Phase I/IIa clinical trial of IMG-7289 for the treatment of high-risk acute...Read More... The post Imago BioSciences completes enrolment in Phase l/lla trial of IMG-7289 appeared first on Drug Development Technology.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks